CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
Consolidative Durvalumab +1 moredrug
Likely dose
Consolidative Durvalumab 1500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04003246
NCT04003246Phase 2Completed
CompareCT.gov

Phase II Concurrent Durvalumab (MEDI4736) and Radiotherapy Followed by Consolidative Durvalumab (MEDI4736) for Stage III Non-Small Cell Lung Cancer (NSCLC)

University of Texas Southwestern Medical Center·interventional·Posted Jul 1, 2019·Updated Mar 21, 2025

In Brief

A Phase 2 clinical trial evaluating Thoracic RT and Durvalumab and Consolidative Durvalumab for Non Small Cell Lung Cancer and Lung Cancer Stage III. Completed, enrolled 10 participants across 1 site.

Detailed Summary

Single arm, Phase II trial of concurrent Durvalumab (MEDI 4736) and radiotherapy followed by consolidative Durvalumb (MEDI 4736) for Stage III Non-Small Cell Lung Cancer (NSCLC)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer, Lung Cancer Stage III
CountriesUnited States
CollaboratorsAstraZeneca

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedJul 1, 2019
Enrollment StartApr 3, 2020
Primary CompletionJun 15, 2022
Study CompletionNov 5, 2024
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 7.0 years ago

Interventions

Thoracic RT and Durvalumabradiation

1500mg every 4 weeks \[Q4W\] intravenous \[IV\], first dose within 3 days of RT initiation

Consolidative Durvalumabdrug

1500mg every 4 weeks \[Q4W\] intravenous \[IV\] up to one year